Xenetic Biosciences Inc (XBIO)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $3.49M
Last updated: Nov 17, 2026 at 4:10 PM ET
Xenetic Biosciences Inc (XBIO) Stock Chart
Xenetic Biosciences (XBIO) has a latest price of $1.54 on Nov 17, 2026, 68.8% below its 52-week high of $4.94. Its price fell 40.8% over the past 12 months. The month-end price fell 99.6% over the 10 years through Oct 2026, a compound annual decline of 42.9%.
Price Chart
From Oct 2016 to Oct 2026, its highest month-end close was $591.84 in Jan 2017 and its lowest $2.05 in Oct 2026, adjusted for splits.
Month-end closes, adjusted for splits. Dividends are not included.
Chart XBIO with Advanced Charting
Daily candlesticks, valuation multiples, side-by-side comparisons and drawings for XBIO.
Free with a GNG account. No credit card.
Price Performance
Over the past 3 months the price fell 54.2%, and over 6 months it fell 46.9%. The month-end price fell 33.4% over the 3 years through Oct 2026, a compound annual decline of 12.7%.
| Period | Change |
|---|---|
| 1 month | -20.2% |
| 3 months | -54.2% |
| 6 months | -46.9% |
| 12 months | -40.8% |
| 12 months, with dividends | -40.8% |
| Period | Change | Per year |
|---|---|---|
| 3 years | -33.4% | -12.7% |
| 5 years | -87.7% | -34.3% |
| 10 years | -99.6% | -42.9% |
Price by Year
Its best calendar year was 2020, when the price rose 41.7%, and its weakest was 2019, when it fell 92.7%.
| Year | Close | Change |
|---|---|---|
| 2026 through Oct 2026 | $2.05 | -5.5% |
| 2025 | $2.17 | -45.6% |
| 2024 | $3.99 | +15.6% |
| 2023 | $3.45 | +21.0% |
| 2022 | $2.85 | -77.9% |
| 2021 | $12.90 | -36.8% |
| 2020 | $20.40 | +41.7% |
| 2019 | $14.40 | -92.7% |
| 2018 | $196.88 | -14.5% |
| 2017 | $230.37 | -55.4% |
Trading Range
The price is 33.0% below its 50-day average of $2.30 and 45.1% below its 200-day average of $2.80.
| Measure | Value | Price vs |
|---|---|---|
| Latest price (Nov 17, 2026) | $1.54 | |
| 52-week high | $4.94 | -68.8% |
| 52-week low | $1.43 | +7.7% |
| 50-day average | $2.30 | -33.0% |
| 200-day average | $2.80 | -45.1% |
Price Risk
Over 3 years, its largest fall from a peak was 85.6%.
| Measure | Value |
|---|---|
| 1-year beta | 1.55 |
| Largest fall, 1 year | -68.1% |
| Largest fall, 3 years | -85.6% |
Advanced Charting Features
Advanced Charting is free with a GNG account, and signed-in members get it in place of the price chart above.
- Valuation multiples. Daily P/E, price to sales, cash flow and book value, PEG and PEGY, drawn behind the price wherever the company's data supports them.
- Price charts and drawings. Candlestick, OHLC, line and area charts with volume and earnings, dividend and split markers, plus trend lines, levels and notes kept in your account.
- Side-by-side compare. Two stocks next to each other on one metric and time span, each chart with its own price scale.
- Projections and saved views. Pick a start and an end point to see the price return, dividends and total return between them, and save views to open later.
Frequently Asked Questions About XBIO
What is XBIO's 1-year price change?
Xenetic Biosciences's price fell 40.8% over the past 12 months. With dividends included, the 12-month total return was -40.8%.
What is XBIO's 5-year price change?
Xenetic Biosciences's month-end price fell 87.7% over the 5 years through Oct 2026, a compound annual decline of 34.3%. These figures leave out dividends.
What is XBIO's 52-week high and low?
Xenetic Biosciences's 52-week high is $4.94 and its 52-week low is $1.43. Its latest price of $1.54 on Nov 17, 2026 is 68.8% below the high.
What is XBIO's beta?
Xenetic Biosciences's 1-year beta against the S&P 500 is 1.55, so its price has moved more than the market over the past year. Its largest fall from a peak over the past year was 68.1%.
Is the XBIO chart free?
Yes. Advanced Charting for XBIO is free with a GNG account, and no credit card is needed. It adds daily candlestick and line charts with volume, valuation multiples, side-by-side comparisons, drawings and saved views.
XBIO pages: Overview, Charting, Earnings, Forecast, Financials, Statistics, Valuation, Competitors